Business Context and Reporting Period
Company: Ultragenyx Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 10, 2016
Event Date: June 6, 2016
Ultragenyx entered into a strategic License and Collaboration Agreement with Takeda Pharmaceutical Company Limited. The agreement establishes a five-year research collaboration focused on a pre-clinical compound and includes options for additional product candidates.
Key Financial Metrics and Transaction Details
This filing details a specific transaction rather than periodic financial performance. Key financial terms include:
- Equity Investment: Takeda agreed to purchase 374,590 shares of Ultragenyx common stock for a total consideration of $40,000,000.
- Pricing Structure: The $40 million purchase price consists of $25,000,000 based on the 30-day volume weighted-average price (VWAP) plus a $15,000,000 cash premium.
- Future Purchase Options:
- Option to require Takeda to purchase an additional $25,000,000 in shares (exercisable 3 months after the effective date, expiring after one year).
- Option to require Takeda to purchase an additional $10,000,000 in shares (contingent on a specific development milestone for a second product candidate).
- License Milestones (Initial Product):
- Development milestones: Up to $7.5 million.
- Regulatory milestones: Up to $75 million.
- Commercial milestones: Up to $150 million.
- Royalties: High-single digits to low-teens on tiered net sales payable to Takeda.
Material Changes and Strategic Shifts
The primary material change is the establishment of a partnership with Takeda, altering Ultragenyx's development landscape:
- Asset Acquisition: Ultragenyx obtained an exclusive license for a pre-clinical compound from Takeda in a pre-determined field of use.
- Development Responsibility: Ultragenyx is responsible for substantially all development activities and costs, except for certain validation activities for option products where Takeda bears costs.
- Geographic Rights: Takeda received an exclusive option for Asian rights to licensed products and an option to exclusively license one of Ultragenyx's products for Japan.
- Liquidity Impact: The transaction provides immediate capital of $40 million, subject to closing conditions.
Outlook, Risks, and Contingencies
Management Commentary and Terms:
- Lock-up and Standstill: Takeda is subject to a 180-day lock-up on the initial shares and a 5-year standstill provision (subject to exceptions).
- Termination: Ultragenyx may terminate the collaboration for convenience after the initial 5-year term. Termination for material breach is possible prior to the 5-year term.
- Regulatory Approval: Closing is subject to Hart-Scott-Rodino (HSR) antitrust review and other customary conditions.
- Private Placement: The shares are sold in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
Risks: The realization of milestone payments and royalties is contingent upon the successful development, regulatory approval, and commercialization of the products. The future equity purchase options are discretionary and contingent on specific milestones or timeframes.
Investor Verification Checklist
- Confirm the closing of the $40 million stock purchase and the receipt of funds.
- Verify the status of the Hart-Scott-Rodino (HSR) antitrust review.
- Monitor the exercise of the $25 million and $10 million future share purchase options by Ultragenyx.
- Track progress on the pre-clinical compound to assess the likelihood of triggering the $232.5 million in potential milestone payments.
- Review the specific "pre-determined field of use" to understand the scope of the exclusive license.